Semaglutide and tirzepatide are the two dominant agents in the GLP-1 class for weight management, and understanding the clinical differences between them is essential for any prescriber in this space. This is not a question of which drug is better - it is a question of which drug is better for which patient. This article provides a thorough side-by-side comparison to support informed, individualized prescribing decisions.
MECHANISM OF ACTION
Semaglutide is a selective GLP-1 receptor agonist. It binds to and activates GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and appetite reduction. It is available as a once-weekly subcutaneous injection under the brand names Ozempic (diabetes indication) and Wegovy (weight management indication), as well as in oral form as Rybelsus.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist - commonly referred to as a dual agonist or twincretin. It was developed by Eli Lilly and is available as a once-weekly subcutaneous injection under the brand names Mounjaro (diabetes indication) and Zepbound (weight management indication). By activating both GIP and GLP-1 receptors simultaneously, tirzepatide appears to produce synergistic rather than simply additive effects on insulin secretion, appetite suppression, and weight loss.
The GIP receptor mechanism is particularly relevant to weight outcomes. GIP receptors in adipose tissue, the central nervous system, and the gastrointestinal tract appear to enhance the appetite-suppressing and metabolic effects of GLP-1 receptor activation. This dual mechanism is the primary explanation for tirzepatide's superior weight loss outcomes in clinical trials.
EFFICACY DATA
The clinical trial data for both agents is robust, and the differences in weight loss outcomes are clinically meaningful.
Semaglutide (STEP trials). The STEP 1 trial, which studied semaglutide 2.4 mg weekly in adults with obesity without diabetes, showed an average weight loss of approximately 14.9 percent of body weight over 68 weeks. Approximately one third of participants lost 20 percent or more of their body weight. The STEP 2 trial in patients with type 2 diabetes showed more modest weight loss of approximately 9.6 percent, consistent with the known attenuating effect of diabetes on GLP-1 response.
Tirzepatide (SURMOUNT trials). The SURMOUNT-1 trial studied tirzepatide at 5, 10, and 15 mg weekly doses in adults with obesity without diabetes. Average weight loss at the highest dose was 22.5 percent of body weight over 72 weeks. Approximately 57 percent of participants at the 15 mg dose lost 20 percent or more of their body weight. The SURMOUNT-2 trial in patients with type 2 diabetes showed average weight loss of approximately 15.7 percent at the highest dose — notably higher than semaglutide's performance in a comparable population.
Head-to-head data. The SURPASS-6 trial provided the most direct head-to-head comparison, studying tirzepatide versus semaglutide in patients with type 2 diabetes. Tirzepatide demonstrated superior weight loss and glycemic control at all doses compared to semaglutide 1 mg. While a direct head-to-head comparison in non-diabetic obesity populations is not yet available, the available data consistently favors tirzepatide for weight loss outcomes.
SIDE EFFECT PROFILES
Both agents share a similar side effect profile driven by their shared GLP-1 mechanism, but there are some differences worth noting.
Common side effects for both agents include nausea, vomiting, diarrhea, constipation, and decreased appetite. These are most prominent during the titration phase and typically improve as the patient acclimates to the medication. Slowed gastric emptying is the primary driver of gastrointestinal side effects for both.
Differences in tolerability. Clinical trial data and real-world experience suggest that tirzepatide may be somewhat better tolerated than semaglutide at equivalent weight loss efficacy levels, though direct tolerability comparisons are complicated by dose differences. Some providers report that patients who experienced significant nausea on semaglutide tolerate tirzepatide better, though this is not universal and the opposite can also occur.
Injection site reactions are generally mild for both agents. Both are administered as once-weekly subcutaneous injections with auto-injector pens, and injection technique considerations are similar.
Serious adverse effects. Both agents carry a black box warning regarding the risk of thyroid C-cell tumors based on rodent studies, though the relevance to humans has not been established. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis is a rare but serious potential adverse effect for both agents.
DOSING SCHEDULES
Semaglutide dosing for weight management (Wegovy) follows a structured titration schedule starting at 0.25 mg weekly for four weeks, increasing to 0.5 mg, then 1.0 mg, then 1.7 mg, with a maintenance dose of 2.4 mg weekly. The full titration to maintenance dose takes approximately 16 to 20 weeks.
Tirzepatide dosing for weight management (Zepbound) begins at 2.5 mg weekly for four weeks, then increases by 2.5 mg increments every four weeks as tolerated, with available doses of 5, 7.5, 10, 12.5, and 15 mg weekly. The titration schedule is flexible and can be adjusted based on tolerability, with a maintenance dose range of 5 to 15 mg weekly.
Both agents are administered once weekly on the same day each week. Dose escalation in both cases should be guided by tolerability - slower titration is always preferable to faster titration when gastrointestinal side effects are present.
COST AND ACCESS CONSIDERATIONS
Cost is a significant real-world factor in agent selection, particularly in cash-pay practices where insurance coverage is not a factor.
Branded semaglutide and tirzepatide carry list prices that place them out of reach for many patients without insurance coverage or manufacturer savings programs. Compounded versions of both agents are available through 503A and 503B pharmacies and are significantly less expensive, though the regulatory landscape for compounded GLP-1 agents continues to evolve and providers should stay current on FDA guidance.
When cost is the primary driver of agent selection, compounded options are often the practical choice for patients who cannot access or afford branded products. The clinical considerations for compounded GLP-1 agents — including sourcing, quality, and documentation — require careful provider evaluation before prescribing.
PATIENT SELECTION: WHICH AGENT FOR WHICH PATIENT
The decision between semaglutide and tirzepatide should be individualized based on several factors.
Consider tirzepatide as a first-line option for patients with a higher BMI where maximum weight loss efficacy is the priority, patients with type 2 diabetes where both glycemic control and weight loss are treatment goals, patients who have previously tried semaglutide with suboptimal weight loss response, and patients who are motivated and engaged and are likely to complete a full titration to higher doses.
Consider semaglutide as a first-line option for patients who have a specific indication for semaglutide based on cardiovascular risk reduction - the SELECT trial demonstrated significant cardiovascular benefit for semaglutide in patients with established cardiovascular disease - patients where cost or access favors semaglutide, and patients who prefer to start with a more established agent with a longer post-market safety record.
Neither agent is universally superior for every patient. Individualizing the decision based on the patient's clinical profile, goals, and circumstances produces better outcomes than defaulting to one agent for all patients.
BOTTOM LINE
Tirzepatide produces greater average weight loss than semaglutide in clinical trials, driven by its dual GLP-1 and GIP receptor mechanism. However the right agent for any individual patient depends on their clinical profile, comorbidities, cost and access considerations, and prior treatment history. Providers who understand both agents thoroughly are best positioned to make individualized prescribing decisions that optimize outcomes for their specific patient population.
